Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT03810612
Active, not recruiting Observational

Patient-reported Outcomes After Percutaneous Coronary Intervention

NCT03810612 · tracked via the Priya Life Science Norway tracker
Phase
Observational
Started
2017-06-12
Last updated
2026-06-23

Condition(s) studied

Coronary Artery Disease

Study summary

The main objective is to investigate i) continuity of care, ii) health literacy and self-management, iii) adherence to treatment, and iv) patient preferences, healthcare utilization and costs, and to determine associations with future short- and long-term health outcomes in patients after percutaneous coronary intervention.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing percutaneous coronary intervention * ≥ 18 years of age * Living at home at the time of inclusion. Exclusion Criteria: * Patients who do not speak Norwegian/Danish * Patients who are unable to fill in the questionnaires due to reduced capacities * Institutionalized patients * Patients with expected lifetime less than one year * Percutaneous coronary intervention without stent implantation * Patients undergoing percutaneous coronary intervention related to Transcatheter Aortic Valve Implantation or Mitraclip examination * Previous enrollment in CONCARD (readmissions).

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Herlev and Gentofte Hospital Copenhagen Denmark
Rigshospitalet, Copenhagen Copenhagen Denmark
Odense University Hospital Odense Denmark
Zealand University Hospital Roskilde Denmark
Haukeland University Hospital Bergen Norway
Oslo University Hospital, Rikshospitalet Oslo Norway
Stavanger University Hospital Stavanger Norway

More Haukeland University Hospital trials in Norway

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03810612 on ClinicalTrials.gov ↗ ← All trials in Norway